Complications associated with CDDP intraperitoneal chemotherapy.

Asia Oceania J Obstet Gynaecol

Department of Obstetrics and Gynecology, Saiseikai Tondabayashi Hospital, Osaka, Japan.

Published: March 1994

As CDDP-ip is known to affect intraperitoneal tumors directly, and reduce CDDP associated adverse reactions, it has been used not only for ovarian cancer but other intraperitoneal tumors. However ip chemotherapy requires catheter placement at the time of laparotomy. We investigated the complications of catheters as an intraperitoneal administration route. The subjects were 84 patients, 39 with temporary catheters and 45 with an implantable port and catheter system. Twenty-seven percent of the temporary catheter patients experienced complications--infection 8%, inflow obstruction 3%, leakage 5%, extrusion 8%, and severe pain 3%. Furthermore, a total of 22% of patients with an implantable port and catheter system experienced complications--inflow obstruction 9%, infection 2%, leakage 4%, and extrusion 7%. Fortunately, no serious complications were observed at our institutions, and the complication incidence seemed lower compared to that of other institutions.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1447-0756.1994.tb00413.xDOI Listing

Publication Analysis

Top Keywords

intraperitoneal tumors
8
implantable port
8
port catheter
8
catheter system
8
leakage extrusion
8
complications associated
4
associated cddp
4
intraperitoneal
4
cddp intraperitoneal
4
intraperitoneal chemotherapy
4

Similar Publications

To clarify the effects of kefir in critical periods of development in adult diseases, we study the effects of kefir intake during early life on gut microbiota and prevention of colorectal carcinogenesis in adulthood. Lactating Wistar rats were divided into three groups: control (C), kefir lactation (KL), and kefir puberty (KP) groups. The C and KP groups received 1 mL of water/day; KL dams received kefir milk daily (10 CFU/mL) during lactation.

View Article and Find Full Text PDF

Malignant transformation is a rare complication of ovarian mature cystic teratoma that occurs in 1-3% of cases. We herein report a case of squamous cell carcinoma originating from mature cystic teratoma of the ovary diagnosed 10 years after initial tumor detection. A 69-year-old woman presented to the Department of Internal Medicine with a seven-month history of abdominal fullness.

View Article and Find Full Text PDF

Objectives: Infantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of infants, predominantly in female and preterm neonates. Propranolol is the mainstay of treatment for IH. Given the short half-life of propranolol regarding β-adrenergic receptor inhibition as well as its side effects, propranolol is administered to infants 2-3 times daily with 1 mg/kg/dose.

View Article and Find Full Text PDF

PerC B-Cells Activation via Thermogenetics-Based CXCL12 Generator for Intraperitoneal Immunity Against Metastatic Disseminated Tumor Cells.

Adv Mater

January 2025

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Environmental Science and Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.

During cancer peritoneal metastasis (PM), conventional antigen-presenting cells (dendritic cells, macrophages) promote tumorigenesis and immunosuppression in peritoneal cavity. While intraperitoneal immunotherapy (IPIT) has been used in clinical investigations to relieve PM, the limited knowledge of peritoneal immunocytes has hindered the development of therapeutic IPIT. Here, a dendritic cell-independent, next-generation IPIT is described that activates peritoneal cavity B (PerC B) cell subsets for intraperitoneal anti-tumor immunity via exogenous antigen presentation.

View Article and Find Full Text PDF

The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer.

Neoplasia

January 2025

Department of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:

T-cell recruiting chemokines are required for a successful immune intervention in ovarian cancer, and also for the efficacy of modern anticancer agents such as PARP inhibitors. The chemokine CX3CL1 recruits tumour-suppressive T-cells into solid tumours, but also mediates cell-cell adhesions, e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!